Drug intelligence / Profile preview

Theia

Development stage: Preclinical
Lead developer: Certis Biologicals
Administration: Topical (agricultural Application)

Overview

Theia is a biological fungicide containing *Bacillus subtilis* strain AFS032321. It is utilized in agriculture for the management of fungal diseases such as blossom blight and brown rot in fruit crops like nectarines and peaches, primarily caused by *Monilinia fructicola*. This biocontrol agent offers an alternative strategy to synthetic fungicides, aiming to reduce chemical input in crop management. Its efficacy can vary when combined with other fungicides, sometimes exhibiting synergistic and other times antagonistic interactions.

Brand names: Theia
Other names: Bacillus subtilis AFS032321

Beyond the preview

Go deeper on Theia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theia.

Explore the full profile